parecoxib has been researched along with cox 189 in 3 studies
Studies (parecoxib) | Trials (parecoxib) | Recent Studies (post-2010) (parecoxib) | Studies (cox 189) | Trials (cox 189) | Recent Studies (post-2010) (cox 189) |
---|---|---|---|---|---|
436 | 186 | 229 | 163 | 49 | 47 |
Protein | Taxonomy | parecoxib (IC50) | cox 189 (IC50) |
---|---|---|---|
Prostaglandin G/H synthase 1 | Homo sapiens (human) | 0.007 | |
Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.076 | |
Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | 0.04 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Frölich, JC; Stichtenoth, DO | 1 |
Deray, G; Montalescot, G; Sibilia, J | 1 |
Elliott, WJ | 1 |
3 review(s) available for parecoxib and cox 189
Article | Year |
---|---|
The second generation of COX-2 inhibitors: what advantages do the newest offer?
Topics: Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Drug Interactions; Etoricoxib; Humans; Isoenzymes; Isoxazoles; Membrane Proteins; Organic Chemicals; Prostaglandin-Endoperoxide Synthases; Pyridines; Sulfonamides; Sulfones | 2003 |
[What do we know about the cardiovascular toxicity of the NSAIDs?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Follow-Up Studies; Humans; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Naproxen; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors | 2006 |
Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Hypertension; Isoxazoles; Lactones; Pyrazoles; Pyridines; Risk; Risk Factors; Sulfonamides; Sulfones | 2010 |